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Abstract
Male gender is a risk factor for the development of hepatocellular carcinoma (HCC) but the mechanisms are not fully
understood. The RNA binding motif gene on the Y chromosome (RBMY), encoding a male germ cell-specific RNA splicing
regulator during spermatogenesis, is aberrantly activated in human male liver cancers. This study investigated the in vitro
oncogenic effect and the possible mechanism of RBMY in human hepatoma cell line HepG2 and its in vivo effect with
regards to the livers of human and transgenic mice. RBMY expression in HepG2 cells was knocked down by RNA
interference and the cancer cell phenotype was characterized by soft-agar colony formation and sensitivity to hydrogen-
peroxide-induced apoptosis. The results revealed that RBMY knockdown reduced the transformation and anti-apoptotic
efficiency of HepG2 cells. The expression of RBMY, androgen receptor (AR) and its inhibitory variant AR45, AR-targeted
genes insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) was analyzed by
quantitative RT-PCR. Up-regulation of AR45 variant and reduction of IGF-1 and IGFBP-3 expression was only detected in
RBMY knockdown cells. Moreover, RBMY positive human male HCC expressed lower level of AR45 as compared to RBMY
negative HCC tissues. The oncogenic properties of RBMY were further assessed in a transgenic mouse model. Liver-specific
RBMY transgenic mice developed hepatic pre-cancerous lesions, adenoma, and HCC. RBMY also accelerated chemical
carcinogen-induced hepatocarcinogenesis in transgenic mice. Collectively, these findings suggest that Y chromosome-
specific RBMY is likely involved in the regulation of androgen receptor activity and contributes to male predominance of
HCC.
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Introduction
Hepatocellular carcinoma (HCC) is one of the leading cancers
in the world [1]. The major identified risk factors include hepatitis
B virus (HBV) or hepatitis C virus (HCV) infection, exposure to
aflatoxins, and male gender [2]. The male-to-female ratio of HCC
reportedly averages 4–5:1 and is particularly higher in HBV-
related HCC (5–11:1) [3]. Epidemiological studies showed that an
elevated level of serum testosterone was significantly associated
with an increased risk of HCC in male HBV carriers [4].
However, male predominance with a ratio of 3–4:1 is also
observed in childhood HCC with early onset, as young as ,10
years of age before puberty, and cannot be explained directly by
androgen effect [5,6].
The androgen receptor (AR) has been shown to contribute to
the male preference of hepatocarcinogenesis in HBV and HCV
carriers [7,8]. The AR protein mediates the action of androgens
and can promote the development of male HCC in mice [9]. After
binding to ligands, AR forms homodimers and activates the
transcription of target genes such as insulin-like growth factor 1
(IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3)
[10,11]. The AR function is regulated by co-activators or co-
repressors [12], the inhibitory isoform AR45 [13], and shorter
CAG repeats (that leads to higher AR activity) in the first exon of
the AR gene [14]. The HBV X protein is a well-known AR co-
activator [15,16] and was reported to contribute to male
predominance in HBV-related human male HCC [17]. In non-
HBV HCC, other unknown gender-specific factors promoting
HCC formation in males have become a major concern.
Dysregulation of Y chromosome-specific genes has been found
in male HCC, but their roles in the male predominance of HCC
so far have not been addressed [18,19]. The RNA-binding motif
gene on the Y chromosome (RBMY) is a male germ cell-specific
expression gene containing RNA recognition motifs at the N
terminus [20]. Its expression is confined to the nuclei of male germ
cells and its deletion may cause the arrest of germ cells at the
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germ cell-specific splicing regulator by modulating the activity of
constitutively expressed splicing factors [22,23]. Its aberrant
activation is detected in about 1/3 of male HCC and
hepatoblastoma tumor tissues, but not in paired non-tumor liver
tissues, female HCC, or other types of cancers [24]. Though
RBMY can interact with AR co-activator Sam68 [25,26], its role
in the AR signaling pathway has not yet been reported.
The present study aimed to evaluate the transformation and anti-
apoptotic efficacy of RBMY in human hepatoma cells, and the
hepatocarcinogenic efficacy of RBMY in transgenic mice, and to
explore its possible underlying molecular mechanisms. Our results
in-vitro, in-vivo, and in clinical human male HCC tissues suggest that
RBMY may enhance AR activity and hepatocarcinogenesis by
reducing the expression of AR inhibitory variant AR45.
Materials and Methods
Human tissue samples
Paired tumor and non-tumor liver tissues were collected from 66
surgical HCC male patients (44 HBV-related, 10 HCV-related, 5
HBV/HCV-related, and 7 non-HBV/HCV-related) at the National
Taiwan University Hospital (NTUH) in 2007. All clinical samples
were obtained following approval of the Research Ethics Committee
of the NTUH (NTUHREC approval No. 9361701139).
Cell culture and transfection
The human hepatocellular carcinoma cell lines HepG2 and
Hep3B were originally obtained from the Bioresource Collection
and Research Center (BCRC, Taiwan). HepG2, Hep3B and
Huh7 (from Dr. Hui-Lin Wu of NTUH Hepatitis Research
Center) cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (HyClone,
Logan, UT). Transfections were performed using Lipofectamine
(Invitrogen/Life Technologies, Carlsbad, CA) according to the
manufacturer’s protocol.
RNA interference
The pSUPER-based strategy was used to knockdown RBMY
expression. RBMY small hairpin RNA (shRNA) was generated by
ligating three 19-nucleotide sequences specific for RBMY SRGY
region (exons 7–10) into the vector (OligoEngine, Inc., Seattle,
WA). The sequences were shown in Table S1. Cells were grown to
80% confluence for transfection and transfected cells were selected
with 300 mg/ml geneticin.
Semi-quantitative RT-PCR and quantitative PCR
Total RNA was extracted using RNeasy Mini kit (QIAGEN,
GmbH, Hilden, Germany) and subjected to reverse transcription
using SuperScript III Reverse Transcriptase (Invitrogen). The
primer sequences and reaction conditions were shown in Table
S1. Quantitative PCR was performed using the TaqMan Gene
Expression Assay mix for target RBMY (Hs00359074_m1) or
endogenous control hypoxanthine phosphoribosyl transferase 1
(Hs99999909_m1) (Applied Biosystems, Foster City, CA). Quan-
titative PCR for AR, AR45, IGF-1, IGFBP-3, and endogenous
control S26 was performed using the MasterMix Plus for SYBR
Green (Applied Biosystems). Amplification signals were detected
by an ABI prism7700 or 7500 Fast Real-Time PCR System
(Applied Biosystems).
Soft agar and survival assays
For soft agar assay, 2500 cells per well in growth medium containing
0.35% agarose were placed on 6-well plates with 0.5% agarose base.
After 14 days of incubation, the colonies were stained with 0.005%
crystal violet at room temperature for 1 hr and counted for each plate.
For survival assay, the HepG2 cells transfected with shRNA
plasmids were treated with 0.5 or 0.75 mM hydrogen peroxide for
24 hr toinduce apoptosis. Cellviability was measured usingtheCell
Proliferation Kit I (MTT) (Roche Diagnostics, Germany). Absor-
bance was measured at 590/690 nm using a MRX microplate
reader (Dynex Technologies, Inc., VA) and cell survival was
expressed as absorbance relative to that of untreated control.
Determination of androgen receptor CAG-repeat length
in human HCC tissues
The genomic region containing the CAG trinucleotide repeat
was PCR-amplified and labelled with FAM, subjected to the ABI
3700 Genetic Analyzer, and scored using the GeneMapper
software (Applied Biosystems). The standard curve to calculate
the CAG repeat number was based on four control samples with
CAG repeat numbers ranging from 17 to 35. Sequencing analysis
was performed on HCC tissues from 66 study subjects with CAG
repeat numbers out of the standard curve.
Establishment of RBMY transgenic mice and follow-up
histopathology
The RBMY coding sequence was amplified and sub-cloned into
the pBS-HCRHPI-A vector with a liver-specific a1-antitrypsin
promoter. The construct was digested with SpeI to generate a
transgene fragment for injection into the pro-nuclei of fertilized
eggs of FVB/N mice. The Institutional Animal Care and Use
Committee of the College of Medicine and College of Public
Health, National Taiwan University approved the animal care and
experimental procedures (IACUC approval No. 20060217).
The mice were sacrificed at 4–24 months old. Their livers were
fixed in 10% neutral-buffered formalin or embedded in OCT
compound (Sakura Finetek, Torrance, CA). Paraffin sections were
stained with hematoxylin and eosin for histopathology examina-
tion, while frozen sections were stained with oil red O to detect
fatty droplet accumulation. The severity of steatosis was estimated
by the percentage of positive staining using a morphologic semi-
quantitative method and classified into grade 1 (,33%), grade 2
(33–66%), or grade 3 (.66%) as described previously [27].
Diethylnitrosamine treatment and histopathology in
mice
In the chemical carcinogen model, 14-day old RBMY
transgenic or control mice randomly received a single intra-
peritoneal injection of diethylnitrosamine (DEN) (Sigma-Aldrich,
Inc., St Louis, MO) at 10 mg/kg of body weight or saline solution
of equal volume, respectively. The mice were sacrificed at 26 and
34 weeks post-treatment. In addition, earlier sacrifice at 14 weeks
was specifically adopted for male mice that were reportedly highly
susceptible to DEN-induced hepatocarcinogenesis. Measurements
of tumor masses visible on the liver surface were recorded.
Microscopic lesions were counted from two representative sections
(50-mm distance) of each mouse liver.
Immuno-histochemistry
Immuno-histochemical staining for the RBMY antigen was
performed on frozen liver sections. After antigen retrieval and
quenching of endogenous peroxidation, the rabbit anti-SRGY
antibody [24] was incubated with sections at 1:400 dilution
overnight at 4uC. HRP-DAB was used as a detection system
(R&D Systems, Inc., Minneapolis, MN) and counter-stained by
hematoxylin.
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The extraction of total protein, Western blot analysis, and anti-
SRGY antibody preparation were performed as described
previously [24]. Briefly, 50 mg of total protein extracted from
individual mouse liver tissue were separated by electrophoresis
using standard SDS-PAGE. The blots were incubated with rabbit
polyclonal anti-SRGY antibodies at 1:5000 dilution and mouse
monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) antibodies (Abcam, Cambridge, UK) at 1:1000 dilution.
Statistical analysis
Statistical differences in the association between AR-CAG
repeats and RBMY, viability assay, fold change in RNA
expression, and DEN treatment analysis were analyzed by two-
tailed Student’s t-test. Difference of steatosis incidences between
the transgenic and control mice was analyzed by Chi-square test.
Soft-agar colony assay was evaluated by one-way ANOVA
followed by t-test. After normalization against S26, relative values
of AR and AR45 expression were analyzed by Student’s t-test with
unequal variance. A p,0.05 was considered statistically signifi-
cant, while a p value between 0.05 and 0.1 was considered as
having a trend of difference.
Results
RBMY knockdown reduced the transformation and
anti-apoptotic efficiencies of HepG2 cells
Natively expressed RBMY in human hepatoma cell line HepG2
was interfered by shRNA specifically targeting to the SRGY
domain of RBMY. Quantitative RT-PCR showed that .95% of
RBMY transcripts were inhibited in pSUPER-680 and pSUPER-
914 transfected HepG2 cells, whereas pSUPER-778 had no
knockdown effect compared to vector transfected cells (Fig. 1A).
Immuno-histochemistry analysis further confirmed efficient knock-
down of RBMY in pSUPER-680 and pSUPER-914 transfected
cells (Fig. 1B). The vector-only transfectants expressed similar
levels of RBMY compared to parental HepG2 cells and were
therefore used as controls for in vitro cell experiments.
The anchorage independence assay showed that RBMY-
expressing HepG2 cells had stronger clonogenic ability compared
Figure 1. RBMY knockdown reduced the transformation and anti-apoptotic efficiencies of HepG2 cells. (A) Quantitative RT-PCR analysis
of RBMY in parental (G2), vector plasmid (VC), pSUPER-680, pSUPER-778, and pSUPER-914 plasmids transfected HepG2 cells. (B) Immuno-
histochemical staining of HepG2 and the corresponding transfectants for RBMY protein. (C) Colony formation of parental or transfected HepG2 cells
on soft agar. (D) Percentage of cell viability by MTT assay post 0.5 or 0.75 mM hydrogen peroxide (H2O2) treatment. Data were presented as
mean6SD in four independent experiments. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0026948.g001
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colony numbers of pSUPER-680 and pSUPER-914 transfected
cells on soft agar were reduced by 45% and 40%, respectively,
compared to empty vector transfectants (Fig. 1C). Colony
formation of RBMY-expressing pSUPER-778 transfectants was
also significantly higher than knockdown transfectants (680 vs.
778, p,0.0001; 914 vs. 778, p=0.001).
The anti-apoptotic abilities of RBMY-expressing and knock-
down HepG2 transfectants were analyzed by survival assay after
hydrogen peroxide treatment. Compared to empty vector
transfectants, the viability of pSUPER-680 shRNA transfectants
with 0.5 or 0.75 mM hydrogen peroxide treatment was reduced
by 46% and 53% (p,0.05), respectively, and those of pSUPER-
914 transfectants were reduced by 34% and 54% (p,0.05),
respectively (Fig. 1D). The viability of RBMY-expressing transfec-
tants pSUPER-778 was 16–19% lower than that of vector
transfectants (p=0.5).
RBMY knockdown increased the expression of inhibitory
androgen receptor variant AR45 and decreased AR
trans-activation activity, while RBMY overexpression
suppressed AR45 levels
It has been reported that Sam68, as an alternative splicing
regulator and interacting protein of RBMY, might modulate AR-
regulated transcriptional activity in prostate cancer cells [25]. To
examine whether the expression ratio of AR and its inhibitory
isoform AR45 were affected by RBMY, semi-quantitative RT-
PCR was performed for RBMY-expressing or knockdown HepG2
cells. Densitometry analysis showed a three-fold increase of AR45
levels in RBMY knockdown transfectants (pSUPER-680 and
pSUPER-914) compared to vector-only (VC) transfectants
(p,0.05) (Fig. 2A). AR45 levels in parental HepG2 cells and
pSUPER-778 transfectants were similar to those in vector
transfectants. There was no significant change in AR levels
between RBMY-expressing and knockdown cells. The AR/AR45
ratios in RBMY knockdown transfectants (pSUPER-680 and
pSUPER-914) were reduced by 2- to 2.5-fold compared to vector-
only (VC) transfectants (Fig. 2A).
As AR45 was reported to suppress AR trans-activation activity
[13], the expression of AR target genes IGF-1 and IGFBP-3 was
assessed and compared between RBMY-expressing and knock-
down HepG2 cells. Quantitative RT-PCR analysis revealed that
RBMY knockdown cells expressed high levels of AR45 but
significantly reduced IGF-1 (p,0.05) and IGFBP-3 (p,0.01) levels
(Fig. 2B), showing that RBMY knockdown correlated with
enhanced AR45 expression and repressed AR activity.
Furthermore, the suppression of AR45 expression by over-
expressing RBMY was also demonstrated in Hep3B and Huh7
cells. AR45 levels were reduced to 42% in RBMY transfected
Hep3B and 60% in Huh7 cells (p,0.05) (Fig. 2C). There was no
significant change in AR levels between RBMY-transfected and
vector-transfected cells.
RBMY expression correlated with reduced AR45 levels
and shorter AR-CAG repeats in human male HCC tissues
Based on the above mentioned results showing that RBMY
expression was associated with lower AR45 levels in HepG2 cells,
AR and AR45 expressions were further compared in RBMY-
expressing and non-expressing human male HCC tissues. Semi-
quantitative RT-PCR showed that RBMY was detected in 35%
(23/66) male HCC tumor tissues, which were confirmed by the
expression of tumor marker alpha fetoprotein (Fig. 2D). Immuno-
histochemical staining confirmed the nuclear expression of RBMY
only in HCC tumor tissues (Fig. 2E).The positive rate of RBMY
transcripts was 36% (16/44) in HBV-related HCC, 40% (4/10) in
HCV-related HCC, 20% (1/5) in HBV/HCV-related HCC, and
29% (2/7) non-viral related HCC. There were no detectable
RBMY transcripts or proteins in the non-tumor portions of the 66
HCC liver tissues.
The expression of AR and AR45 variant in seven RBMY-
expressing and five non-expressing male human HCC tissues was
determined by 2exp
(2DDCt) method for relative quantification. The
mRNA levels in HCC tissues were normalized against the internal
control S26 and compared to the levels in vector-only HepG2
transfectants. Significantly lower levels of AR45 were detected in
RBMY-expressing male HCC compared to non-RBMY express-
ing HCC tissues (p,0.05) (Fig. 2F), reflecting RBMY suppression
on AR45 transcription. There was no significant difference of AR
levels between RBMY-expressing and non-expressing HCC
tissues.
To further assess the association between RBMY and AR
activity, the CAG-repeat length of the AR gene, an AR activity-
associated factor, was determined in RBMY-expressing or non-
expressing male human HCC tissues. The mean CAG-repeat
length in 49 HBV-related male HCC tissues (RBMY positive/
negative=17/32) was significantly shorter in those with than in
those without RBMY expression (21.062.8 vs. 22.962.8, p,0.05).
The association of CAG-repeat length and RBMY expression
revealed a trend of difference (21.462.54 vs. 22.762.75, p=0.064)
when non-HBV HCC tissues were included (RBMY positive/
negative=23/43).
RBMY transgenic mice developed hepatic fatty change
and neoplastic lesions
Transgenic mice with liver-specific expression of RBMY were
established (Fig. 3A). Western blot showed low RBMY expression
in transgenic founders RF1 and RF2, but high RBMY level in
RF4 and RF6 (Fig. 3B). There was no transgenic RBMY detected
in the brain, heart, kidney, lung, spleen, stomach, or testis by RT-
PCR (Fig. 3C), indicating a liver-specific expression of RBMY in
transgenic mice. Quantitative RT-PCR results further supported
RF4 as a high expression founder (Fig. 3D). IHC staining showed
that RBMY was mainly located in the nucleus of transgenic mice
liver tissues (Fig. 3E).
Hepatocellular changes were analyzed from liver sections of 79
transgenic mice and 30 control FVB/N mice. High RBMY-
expressing RF4 founders (RF4-19 and RF4-21) displayed more
severe fatty deposit than low RBMY-expressing RF2 founders
(RF2-62 and RF2-390) (Fig. 3F). In RBMY transgenic mice, the
incidence of developing moderate-to-severe hepatic steatosis was
60–89% (average 73%), which was ,2.5-fold higher than that of
the control group (average 30%, p,0.001) (Table 1). RBMY
expression did not increase fibrosis or cirrhosis in the transgenic
mice model.
Among the 45 transgenic mice which were older than 15
months, three of them developed hepatic cancerous lesions
(Table 1). A nodule (1 mm in diameter) was found in the right
lobe of RF1-278 mouse (15 months) and histological examina-
tion revealed a pre-neoplastic lesion (Fig. 4A–C). The RF4-21
mouse (24 months) had an adenoma nodule (4 mm in diameter)
in the right lobe (Fig. 4D–F) while RF2-390 (21 months) had
moderately differentiated HCC (6 mm in diameter) in the
median lobe (Fig. 4G–I). Medium-to-severe fatty changes were
observed in the tumor parts of the three mice. None of 17
control mice older than 15 months developed hepatic
cancerous lesions.
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hepatocarcinogenesis
The tumor-promoting effects of RBMY were further assessed in
the chemical carcinogenesis model. Because of the high suscep-
tibility of male mice to DEN, male groups were sacrificed at 14
weeks post-treatment. A higher incidence of cancerous lesions was
observed in transgenic male mice as compared to that in the
control group (12/14 vs. 5/12, p,0.05). At 34 weeks post-
treatment, male RBMY transgenic mice developed more tumors
with diameter .3 mm compared to the control group (52 vs. 19,
p,0.05) (Table 2). There was also a higher incidence of trabecular
cancerous lesions in female transgenic mice compared to the
Figure 2. RBMY expression correlated with reduced androgen receptor AR45 variant in human hepatoma cell lines and male HCC
tissues. (A) Semi-quantitative RT-PCR and densitometric analysis of RBMY, AR and AR45 in parental (G2), vector plasmid (VC), pSUPER-680, pSUPER-
778, and pSUPER-914 plasmids transfected HepG2 cells. (B) Quantitative RT-PCR analysis of RBMY, AR45, IGF-1 and IGFBP-3 in RBMY knockdown
transfectants (680 and 914) and non-knockdown transfectants (VC and 778). Values were normalized against the internal control S26. Data are
mean6SD folds over vector control (VC). (C) Quantitative RT-PCR analysis of AR and AR45 in vector control or RBMY transfected Hep3B and Huh7
cells. Data are mean6SD folds over vector control (VC). (D) Semi-quantitative RT-PCR analysis of RBMY in the tumor (T) and non-tumor (N) parts of
human male HCCs. S26 is an internal control and alpha fetoprotein (AFP) as a tumor marker. (E) Immuno-histochemical staining of nuclear RBMY
protein in HCC tissues only (6400). (F) AR and AR45 mRNA expression in 7 RBMY-expressing and 5 non-expressing human male HCC tissues. The
results were the mean of three different experiments. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0026948.g002
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10 vs. 3/13, p,0.01) post DEN treatment (Table 2).
Discussion
RBMY is regarded as a testis-specific splicing factor in
spermatogenesis [22,23]. It has been reported to be expressed
in more than one-third of human male HCC tissues [24]. This
study further demonstrates that RBMY knockdown correlates
with increased AR45 variant expression and reduced anchor-
age independent growth and anti-apoptotic abilities of human
hepatoma cell line HepG2. AR45 isoform is reported to act as a
dominant-negative inhibitor of AR function through the
formation of AR-AR45 heterodimers [13]. We also demon-
strate that RBMY knockdown reduces AR trans-activation
a c t i v i t yi nH e p G 2c e l l s .T h e r e f o r e ,R B M Ym a yf u n c t i o na sa
male-specific oncogene and increase the risk of human male
hepatocarcinogenesis through regulation of AR gene expression
and activity.
The AR gene, rather than androgen, has been shown to play a
key role in the male predominance of HCC in a transgenic HBV
mouse model [17]. Human AR is composed of N terminal
transactivation domain, a central DNA-binding domain, and a C
terminal ligand-binding domain. AR45, a naturally occurring
variant form of human androgen receptor, lacks the N-terminal
domain required for full ligand activated transcriptional activity
[13]. The inverse association of AR and AR45 expression has been
observed in human heart and muscle tissues with the highest levels
of AR45 and the lowest levels of AR [13]. In this study, RBMY
knockdown increases expression of AR45 in human hepatoma
HepG2 cell line, while RBMY overexpression reduces AR45 levels
in Hep3B and Huh7 cell lines. Moreover, RBMY-positive human
male HCC tissues express lower AR45 levels compared to RBMY-
negative HCC. The down-regulation of AR target genes IGF-1
and IGFBP-3 in RBMY knockdown HepG2 cells further illustrates
the enhancing effect of RBMY on AR trans-activation activity.
HBV X protein has been reported to function as a virus-encoding
AR co-activator that significantly contributes to the male
Figure 3. Characterization of RBMY transgenic mice. (A) Genetic map of the 4.2 kb RBMY transgene, including a hepatic locus control region
from the apolipoprotein E gene (ApoE-HCR), liver-specific a1-antitrypsin promoter (hAAt-Pr), truncated factor IX intron (hFIX-IA), and bovine growth
hormone polyadenylation signal (bghpA). (B) Western blot analysis of RBMY prepared from the livers of individual transgenic (RF1-6, RF2-265, RF4-89,
RF6) and control (NT1, NT2) mice. (C) Liver-specific expression of RBMY in transgenic mice by RT-PCR using GAPDH as an internal control. Reactions
without template RNA (RTC) or cDNA (NTC) were negative controls. (D) Expression of RBMY in transgenic (RF1-176, RF1-278, RF2-62, RF2-390, RF4-19,
RF4-21) and control (NT1, NT2) mice by quantitative RT-PCR. (E) Immuno-histochemical staining of transgenic (RF4-89) and control (NT) mice liver
tissues for RBMY. Transgenic mouse showed nuclear staining for RBMY (6400). (F) Oil red staining showed hepatic fatty changes in control mice (NT1
and NT2), low RBMY (RF2-62 and RF2-390) and high RBMY (RF4-19 and RF4-21) transgenic mice (6400).
doi:10.1371/journal.pone.0026948.g003
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Mice Gender Age Liver/body Incidence of Incidence of
(Mice No.) (days) weight grade 2/3 pre-neoplastic lesions
(6100) steatosis /adenoma/HCC
TgRBMY F (37) 496.46158.3 4.4960.97 89%
** 1/37
M (42) 474.26154.0 4.6961.02 60%
* 2/42
NT F (15) 439.96191.8 5.0961.05 40% 0/15
M (15) 433.56185.1 5.2161.14 20% 0/15
TgRBMY F+M (79) 484.66155.4 4.6061.00 73%
** 3/79
NT F+M (30) 436.76185.3 5.1561.08 30% 0/30
The liver frozen sections from control (NT) and RBMY transgenic (TgRBMY) mice were stained with oil red O and classified to grade 2 and 3 with 33,66% and .66%
positive stain, respectively.
The paraffin sections were stained with hematoxylin and eosin for histopathology examination.
Values are shown as mean 6 SD.
*p,0.05;
**p,0.001; transgenic vs. control mice; by Chi-square test.
doi:10.1371/journal.pone.0026948.t001
Figure 4. RBMY induced hepatic neoplastic changes in transgenic mice. (A–C) Pre-neoplastic lesion in a 15-month-old male mouse RF1-278.
(D–F) Adenoma (AD) in a 24-month-old female mouse RF4-21. (G–I) HCC in a 21-month-old male mouse RF2-390. Magnification: B, E, H,650; C, F, I,
6200.
doi:10.1371/journal.pone.0026948.g004
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cannot explain the gender disparity of non-HBV-related HCC.
Similar ratio of RBMY expression in HBV-related, HCV-related,
and non-viral-related male HCCs suggests that RBMY may be a
common risk factor increasing male susceptibility for liver cancer.
Our findings provide a novel mechanism interpreting the male
predominance in all types of liver cancers through the Y
chromosome-specific RBMY gene.
The AR45-specific exon 1B lies between the first and the second
exons of the AR gene. Two hypothetical regulatory mechanisms
for AR45 synthesis have been proposed, including a transcrip-
tional control by a novel promoter upstream of exon 1B or an
alternative splicing event [13]. RBMY acts as a testis-specific
splicing regulator and reportedly interacts with RNA-binding
protein Sam68 in the testis [26]. Sam68 is a ubiquitous splicing
regulator and also a downstream target of the Src signaling
pathway [28,29]. It is thus far unclear whether or not RBMY
either directly regulates AR45 transcription/splicing or via
interacting with Sam68. In addition, Sam68 is considered an
AR co-activator as it can modulate AR transcriptional activity in
prostate cancers [25]. The Src signaling pathway also has been
shown to be critical for the HBV X protein-mediated enhance-
ment of AR function [30]. Whether RBMY is involved in the
Sam68-mediated Src signaling pathway is an interesting issue to be
studied in the future.
The oncogenicity of RBMY has been shown by the transfor-
mation of mouse fibroblast cell line NIH3T3 [24]. This study
further demonstrates that RBMY enhances liver carcinogenesis in
vivo in a transgenic mouse model. The reported spontaneous liver
tumor growth rates are 3% and 0% in 24 month-old male and
female wild type FVB/N mice, respectively [31]. RBMY
transgenic mice developed liver tumors in 8.7% (2/23) of male
and 4.5% (1/22) of female mice older than 15 months, which are
more than 2-fold higher than the spontaneous liver tumor
incidences.
In the model of DEN-induced hepatocarcinogenesis, the
significance of RBMY enhancing effect on cancerous lesion
formation is observed as early as 14 weeks post-treatment in male
transgenic mice. In addition, larger tumors (diameter $3 mm)
developed in transgenic male mice at 34 weeks, indicating RBMY
enhancement on DEN-induced hepatocarcinogenesis. Even fe-
male RBMY transgenic mice also have significantly increased
incidence of cancerous lesions at both 26 and 34 weeks post-
treatment. Although the wild type female mice are resistant to
DEN carcinogenesis due to the protective effect of estrogen-
mediated inhibition of IL-6 production by Kupffer cells [32,33],
the results here demonstrate the delivery and activation of a male-
specific RBMY gene accelerated liver cancer development even in
female transgenic mice.
In conclusion, RBMY knockdown elicits inhibitory effects on
the transformation and anti-apoptotic abilities of the human
hepatoma cell line HepG2. The inhibitory effect of RBMY on
AR45 levels is demonstrated in RBMY knockdown HepG2 cells
and RBMY over-expressing Hep3B and Huh7 cells. Therefore,
the oncogenic mechanism of RBMY may be linked to its
regulation of AR trans-activation activity by the increase of
AR45 variant, the inhibitor of AR. AR45 expression detected in
RBMY-expressing human male HCC is also significantly lower
compared to non-expressing HCC tissues. Furthermore, RBMY
exhibits tumor-promoting activity in vivo in a transgenic mice
model and accelerates the development of neoplastic lesions in a
diethylnitrosamine-induced hepatocarcinogenesis animal model.
The carcinogenic effect in hepatoma cell line and human HCC
tissues, along with in vivo tumor promotion in the transgenic mice,
provides a novel role of RBMY as a male-specific oncogene to
explain the male predominance of liver cancer.
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Table 2. Incidence of hepatocarcinogenesis induced by DEN in RBMY transgenic and control mice.
Gender RBMY 14 wks 26 wks 34 wks
Incidence of Incidence of Incidence of No. tumor
cancerous cancerous lesions cancerous lesions $3m m
lesions (No. mice) (No. mice) (No. Mice) (No. mice)
F + ND 78% (7/9)
** 90% (9/10)
** 0( 1 0 )
F 2 ND 10% (1/10) 23% (3/13) 0 (13)
M + 86% (12/14)
* 100% (5/5) 100% (6/6)
52 (6)*
M 2 42% (5/12) 90% (9/10) 100% (7/7) 19 (7)
RBMY transgenic or control mice (14-day old) received a single intra-peritoneal injection of diethyl nitrosamine (DEN) 10 mg/kg of body weight. They were euthanized
by cervical dislocation at 26 and 34 weeks for females, and at 14, 26, and 34 weeks for males after injection.
ND, not determined.
*p,0.05;
**p,0.01, RBMY-positive vs. RBMY-negative mice; by Student’s t test.
doi:10.1371/journal.pone.0026948.t002
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